IMI2 – Call 9
IMI2 – Call 9 was launched on 27 April 2016 with the following topics:
- Addressing the clinical burden of Clostridium difficile infection (CDI): Evaluation of the burden, current practices and set-up of a European research platform (part of the IMI New Drugs for Bad Bugs (ND4BB) programme)
- Development of immune tolerance therapies for the treatment of rheumatic diseases
- Data quality in preclinical research and development
- Next generation of electronic translational safety
- Identification and validation of biomarkers for non-alcoholic steatohepatitis (NASH) and across the spectrum of non-alcoholic fatty liver disease (NAFLD)
- Joint influenza vaccine effectiveness studies
More information on the topics can be found in IMI’s press release and in the Call text. Other relevant documents, including documents for applicants, the list of expert reviewers, and the independent observers’ reports of the evaluations, can be found on the IMI2 Call documents page.
Projects
The projects resulting from IMI2 - Call 9 are:
- COMBACTE-CDI - Combatting bacterial resistance in Europe - Clostridium difficile infections
factsheet | website - DRIVE - Development of robust and innovative vaccine effectiveness
factsheet | website - EQIPD - European quality in preclinical data
factsheet | website - eTRANSAFE - Enhacing translational safety assessment through integrative knowledge management
factsheet | website - LITMUS - Liver investigation: testing marker utility in steatohepatitis
factsheet | website - RTCure - Rheuma tolerance for cure
factsheet | website
Proposal submission information
- Proposals submitted: 17
- Inadmissible & ineligible proposals: 0
- Proposals recommended for funding: 6
- Proposals not recommended for funding: 11